$314,286 is what Propanc Health Group Corp (OTCMKTS:PPCH) will receive from an institutional investor. The investment whose focus is on research and development will enhance the progress of PPCH’s study on its lead product, PRP. Speaking about the support received, Propanc’s Chief Executive Officer, James Nathanielsz said that it was a significant move towards the tracking and execution of the company’s plans.

Nathanielsz also confirmed that the company had been receiving immense support from its lead investor which is one way of unlocking its value and that of its shareholders. A lot of capital has already been channeled into the development of PRP.

Is PRP study by Propanc worth it?

Pancreatic, ovarian and colorectal cancers are some of the solid tumors a majority of cancer patients are seeking treatments for. The emerging healthcare company is hence designated towards the development of new and proprietary treatments. The study is worth it because it tends to explain the affiliation between the level of exposure of PRP in the blood and its toxicity.

The study will adhere to Good Laboratory Practice (GLP), method validation of an IR (infrared) that analysis the metabolism and distribution of PRP in blood plasma. There is a lot of anticipation from this study and probably the reason there has been more investment running into millions.

Propanc is up to much other than just the PRP study

PPCH is doing much more behind the scenes. The current report talks of ongoing negotiations between the company and a contract manufacturer development. The negotiations are about Good Manufacturing Practice (GMP) manufacture of finished drug product for PRP that will be used for first-in-man studies.

The company is also fast-tracking the development of proenzyme related oncology products into clinical trials. The trials have an initial target of pancreatic and ovarian cancers before moving to colorectal cancer. It has already developed a formulation of anti-cancer compounds a simple indication of its commitment to the cancer patients. The future target is the development of its lead product such that it will be used for early stage cancer treatment as well as treatment of pre-cancerous diseases.

Iddriven Inc (OTCMKTS:IDDR) Short Interest On A Decline

Iddriven Inc (OTCMKTS:IDDR) stock remained unchanged as of close of business last week investors having reacted to the company forecasting robust growth for the year. However, short interest on the stock continues to drop, as the street remains bullish about the company’s prospects.

Fueling the bullish momentum on the stock is the number of channel partnerships the company has signed in the recent past. With the company, having set its eyes on accruing some market share on Identity Access Management solutions, it has signed a distribution agreement with Oxford Computer Group for its IDaaS solution.

Iddriven Inc (OTCMKTS:IDDR) also has a deal in place with Zeva a leading reseller of enterprise technology, a partnership that should help bolster its prospects in the North American market. The bullish sentiment around the company is expected to continue growing CEO, Arend Verweij, having reiterated they are in pursuit of growth opportunities in Europe as well.